stoxline Quote Chart Rank Option Currency Glossary
  
OKYO Pharma Limited (OKYO)
1.49  0 (0%)    03-28 16:00
Open: 1.515
High: 1.515
Volume: 18,610
  
Pre. Close: 1.49
Low: 1.45
Market Cap: 50(M)
Technical analysis
2024-03-28 4:53:22 PM
Short term     
Mid term     
Targets 6-month :  1.95 1-year :  2.21
Resists First :  1.67 Second :  1.89
Pivot price 1.5
Supports First :  1.29 Second :  1.08
MAs MA(5) :  1.48 MA(20) :  1.47
MA(100) :  1.61 MA(250) :  1.6
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  23.9 D(3) :  24.6
RSI RSI(14): 49.6
52-week High :  3.25 Low :  0.92
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ OKYO ] has closed above bottom band by 45.7%. Bollinger Bands are 43.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.52 - 1.53 1.53 - 1.53
Low: 1.42 - 1.44 1.44 - 1.45
Close: 1.47 - 1.49 1.49 - 1.5
Company Description

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

Headline News

Mon, 25 Mar 2024
OKYO Pharma Ltd expected to post a loss of 11 cents a share - Earnings Preview - XM

Sat, 23 Mar 2024
OKYO Pharma (NASDAQ:OKYO) Price Target Raised to $7.00 at HC Wainwright - Defense World

Sat, 23 Mar 2024
OKYO Pharma (LON:OKYO) Stock Price Down 24.3% - Defense World

Fri, 22 Mar 2024
OKYO Pharma says OK-101 shows statistically significant improvements for dry eye symptoms - Proactive Investors USA

Fri, 22 Mar 2024
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of ... - Yahoo Finance

Thu, 21 Mar 2024
OKYO Pharma to host event featuring Phase 2 trial results for OK-101 in dry eye disease - Proactive Investors USA

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 33 (M)
Held by Insiders 1.364e+007 (%)
Held by Institutions 25.7 (%)
Shares Short 51 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.318e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -173.5 %
Return on Equity (ttm) -2 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) -0.15
Sales Per Share 0
EBITDA (p.s.) -0.28
Qtrly Earnings Growth -0.7 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -8 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 59.04
Stock Dividends
Dividend 0
Forward Dividend 64630
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android